Latham & Watkins has advised Ardian, a world leading private investment house, on the sale of its majority stake in Unither Pharmaceuticals (Unither), a global leader in the development and manufacturing of sterile unit-doses, to a consortium of new and existing investors comprised of GIC, IK Partners, Keensight, and Parquest and led by Eric Goupil, CEO of Unither.
Founded in 1993, Unither is a global player in the development and manufacturing of sterile unit-doses (Blow-Fill-Seal technology) for the pharmaceutical industry addressing the ophthalmology, respiratory and rhinology markets. The company runs seven manufacturing sites in addition to its Research and Development center, and is present in France, the United States, China, and Brazil.
The Latham Paris team was led by corporate partners Gaëtan Gianasso and Simon Lange, with corporate associate Thibault Burnier. Advice was provided on finance matters by partner Carla-Sophie Imperadeiro; and on antitrust matters by partner Mathilde Saltiel with associate Anne-Claire Théry.